Stefan Beyer
InvestorExecutive Advisor at Ampersand
About
Stefan Beyer joined Ampersand as an Executive Advisor in 2024, drawing on more than 20 years in leadership and business development across the life sciences sector. He previously served as CEO and later President of Vibalogics, a CDMO focused on oncolytic viral vectors and viral vector vaccines that was acquired by Recipharm in 2022, and has experience converting family-owned businesses into investor-backed growth companies. He holds a Ph.D. in biology and biotechnology with a focus on the molecular biology of natural product-producing microorganisms.
Invests in
Biotech
Investments
Board seats
Purna PharmaceuticalsVivebiotech
Per the firm's website.
Colleagues at Ampersand
Aditya V. Goel
Associate at Ampersand
Benoit P. Bouche
Operating Partner at Ampersand
Cole S. Aldrich
Senior Associate at Ampersand
David Q. Anderson
General Partner at Ampersand
Dean D. Schauer
Operating Partner at Ampersand
Elias J. Laimboeck
Senior Associate at Ampersand
Emanuele M. Delfino
Associate at Ampersand
Eric B. Lev
General Partner at Ampersand
Frequently asked questions
- Who is Stefan Beyer?
- Stefan Beyer joined Ampersand as an Executive Advisor in 2024, drawing on more than 20 years in leadership and business development across the life sciences sector. He previously served as CEO and later President of Vibalogics, a CDMO focused on oncolytic viral vectors and viral vector vaccines that was acquired by Recipharm in 2022, and has experience converting family-owned businesses into investor-backed growth companies. He holds a Ph.D. in biology and biotechnology with a focus on the molecular biology of natural product-producing microorganisms.
- Where does Stefan Beyer work?
- Stefan Beyer is Executive Advisor at Ampersand.
- What does Stefan Beyer invest in?
- Stefan Beyer invests in Biotech.
- What boards does Stefan Beyer sit on?
- Stefan Beyer holds tracked board seats at Purna Pharmaceuticals, Vivebiotech.